Is IMWG frailty-score-adjusted dosing the right approach to improve toxicity and outcomes in FRAIL patients? Results from the UK-MRA FiTNEss trial in newly diagnosed myeloma patients ineligible for ASCT.
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Charlotte Pawlyn, Kara-Louise Royle, Ethan Senior, Dax Everritt, Jenny Bird, Stella Bowcock, Bryony Dawkins, Mark Drayson, Sharon Gillson, Catherine Olivier, Matthew Jenner, John Jones, Martin Kaiser, Bhuvan Kishore, David Meads, Neil Rabin, Roger Owen, Ruth de Tute, Christopher Parrish, Alan Chant, David Cairns, Graham Jackson, Gordon Cook
Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, University of Leeds, University Hospitals Bristol NHS Foundation Trust, King's College Hospital NHS Foundation Trust, Queen Mary's Hospital Sidcup, King's College Hospital, University of Birmingham, University Hospital Southampton NHS Foundation Trust, Brighton and Sussex Medical School, University of Sussex, Eastbourne District General Hospital, University Hospitals Birmingham NHS Foundation Trust, University College London Hospitals NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust, Newcastle University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417013324
Cites:
Cited by:
Related to: